In a corner of telehealth often criticized as a “script mill,” Mochi Health is wagering that the real differentiator is the opposite: keeping patients with a provider they trust over the long term.
The knock on direct-to-consumer telehealth is that it optimizes for the transaction. A patient arrives, a questionnaire is processed, a prescription ships, and the relationship effectively ends, until the next refill or the next condition sends them back through the funnel.
The model is efficient for simple needs but poorly suited to the chronic, complex conditions that account for most of healthcare’s costs and difficulties.
Mochi Health, founded by Myra Ahmad in 2022, is building around the opposite premise: that continuity, not throughput, is what patients actually need and what a telehealth company should be designed to deliver.
Mochi’s stated aim is to keep a patient with the same provider across many needs and over time, an approach Ahmad argues is both better care and a more defensible business.
The problem continuity is meant to solve
Ahmad traces the company to a structural failure she observed in research: patients falling out of care in the gaps between specialists.
“Our healthcare system is optimized for billing codes rather than clinical outcomes,” she told Women of Wearables in April 2026.
“Patients bounce from specialist to specialist, yet no one seems to ‘own’ their care.” When clinicians are paid by the volume of billable encounters rather than by whether patients improve or stay in treatment, nothing in the system rewards keeping a patient connected to a single, accountable relationship.
A one-off prescription model, however convenient, reproduces that gap online. It can dispense a drug, but it cannot easily notice when a treatment is failing, adjust a plan as a patient’s situation changes, or coordinate care across the several conditions that often travel together.
Continuity is Mochi’s proposed remedy. A standing relationship that persists between prescriptions rather than resetting at each one.
What continuity looks like on the platform
In practice, Mochi structures care around a chosen provider and an ongoing support team rather than a single visit.
Patients select their own provider and, according to the company’s site, receive unlimited access to a physician and care team, nutrition coaching with a registered dietitian, in-app messaging, and 24/7 support throughout their journey.
The company frames care as continuing well beyond the first prescription, and its member testimonials lean on the same theme, including one patient who says she chose Mochi because she “wanted real support, not just a prescription.”
That continuity is designed to span conditions as well as time. Ahmad has said patients can stay with a trusted provider across 15-plus treatment areas and more than 120 conditions, and that the expansion beyond weight loss was driven by patients asking their Mochi providers to manage more of their care.
The destination she describes is a “primary care home,” a single trusted relationship through which a patient can manage the full range of their health rather than reassembling it across disconnected practices.
Around-the-clock access to providers, nutritionists, and dietitians is meant to make that relationship continuous rather than episodic.
Why it matters most for women
Ahmad is direct that continuity is not an abstract ideal but a practical necessity. “For women managing their obesity, as well as additional health complications such as PCOS, perimenopause, or fertility issues, having continuity in care is essential,” she has said.
A model that keeps a patient with one provider who understands the whole picture is, in her framing, what good care for these patients was always supposed to look like.
Mochi’s own testimonials echo the point, including a member who said the platform was the first place her PCOS and GLP-1 journey “were finally taken seriously.”
The business logic
A company built on one-off prescriptions has to keep re-acquiring patients, an expensive treadmill in a category where marketing costs are high.
A company built on retained relationships can grow by deepening them, adding treatment areas as patients ask for them rather than buying new customers for each.
Mochi’s broadening from weight loss into dermatology, reproductive health, menopause, and longevity follows that logic: each new area is a reason for an existing patient to stay rather than a new patient to chase. Retention, in this model, is both the clinical goal and the growth engine.
The caveats
Continuity is easier to promise than to sustain. Mochi’s claims warrant the usual scrutiny. Keeping patients engaged over the long term is difficult for any provider.
Broadening into many conditions also raises the bar: a platform that promises continuity across 120-plus conditions takes on the challenge of maintaining quality and genuine coordination across all of them, rather than simply offering more checkout lanes.
There is a real risk that “continuity” becomes a marketing layer over what is still, functionally, a series of prescriptions.
The fairest reading is that Mochi has identified a genuine weakness in transactional telehealth and built its model to address it.
In a field often accused of selling scripts, Mochi is betting that the thing worth selling is the relationship that outlasts them.
